|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0017431,
umls-concept:C0032893,
umls-concept:C0035525,
umls-concept:C0037747,
umls-concept:C0087111,
umls-concept:C0205191,
umls-concept:C0205210,
umls-concept:C0205466,
umls-concept:C0205547,
umls-concept:C0681842,
umls-concept:C0871261,
umls-concept:C1521828,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C2911692
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
2007-4-3
|
|
pubmed:abstractText |
Sustained virological response rates of up to 52% have been obtained with peginterferon alpha2a (40 kDa) plus ribavirin in patients suffering from chronic hepatitis C genotype 1 in randomized-controlled trials. Aim: To assess early virological response and its clinical utility in predicting an sustained virological response in patients suffering from chronic hepatitis C genotype 1 in routine clinical practice in Spain.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0269-2813
|
|
pubmed:author |
pubmed-author:AntónMM,
pubmed-author:BarniolRR,
pubmed-author:BenítezAA,
pubmed-author:CasanovasTT,
pubmed-author:DíazFF,
pubmed-author:DalmayFF,
pubmed-author:Del OlmoJJ,
pubmed-author:DiagoMM,
pubmed-author:DomínguezAA,
pubmed-author:EnríquezJJ,
pubmed-author:ErañaLL,
pubmed-author:GarijoJ MJM,
pubmed-author:GavilánJ CJC,
pubmed-author:HuarteMM,
pubmed-author:JiménezEE,
pubmed-author:MontoroMM,
pubmed-author:Moreno-OteroRR,
pubmed-author:Muñoz-SánchezMM,
pubmed-author:OlcozJ LJL,
pubmed-author:OlveiraAA,
pubmed-author:OriveMM,
pubmed-author:PérezRR,
pubmed-author:PamplonaXX,
pubmed-author:PlanasRR,
pubmed-author:PorteZZ,
pubmed-author:Romero-GómezMM,
pubmed-author:RosetMM,
pubmed-author:RothII,
pubmed-author:Sánchez-GaldónSS,
pubmed-author:Sánchez-RuanoJJ,
pubmed-author:SalmerónJJ,
pubmed-author:SilleroCC,
pubmed-author:SoláRR,
pubmed-author:UribarrenaRR
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
25
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
899-906
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:17402993-Adult,
pubmed-meshheading:17402993-Antiviral Agents,
pubmed-meshheading:17402993-Drug Therapy, Combination,
pubmed-meshheading:17402993-Female,
pubmed-meshheading:17402993-Hepatitis C, Chronic,
pubmed-meshheading:17402993-Humans,
pubmed-meshheading:17402993-Interferon-alpha,
pubmed-meshheading:17402993-Male,
pubmed-meshheading:17402993-Middle Aged,
pubmed-meshheading:17402993-Polyethylene Glycols,
pubmed-meshheading:17402993-Recombinant Proteins,
pubmed-meshheading:17402993-Ribavirin,
pubmed-meshheading:17402993-Treatment Outcome
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Treatment of chronic he1patitis C genotype 1 with peginterferon-alpha2a (40 kDa) plus ribavirin under routine clinical practice in Spain: early prediction of sustained virological response rate.
|
|
pubmed:affiliation |
Hospital General de Valencia, Valencia, Spain. mdiagom@meditex.es
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
